Five glycomics projects have been awarded funding to develop new tools, diagnostics and therapeutics to improve health for Canadians.
Catégorie : Communiqué de presse
PlantForm and UBC researcher receive GlycoNet funds to develop novel treatment for Type-2 diabetes
PlantForm Corporation has teamed up with a University of British Columbia research group led by Dr. Joerg Bohlmann to develop a novel plant-based treatment option for Type-2 diabetes and obesity, with support from GlycoNet.
GlycoNet start-up GlyCa Biosciences Inc. and Huron Innovation Inc. partner to improve prostate cancer detection
This partnership will launch the clinical trial of a new blood test to perfect early detection and diagnosis of clinically significant prostate cancer.
GlycoNet and Partners Invest $6.5 Million in Carbohydrate Research with One Health Focus
This investment will support state-of-the-art glycomics research that focuses on different aspects of One Health—human, animal and environmental health.
GlycoNet Integrated Services awarded $10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund
Glycomics in Canada receives crucial funding boost to further life-saving research and biotechnology development.
GlycoNet startup, ABOzymes, completes seed financing round to fund development of technology to enable universal organ transplants and blood transfusions
Glycomics is an integral part of ABOzymes’ life-saving research and technology development.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
GlycoNet joins national industry association to drive economic growth in the biotechnology sector
As a member of BIOTECanada’s network, GlycoNet aims to mobilize glycomics research into tangible and sustainable innovation for Canadians.
GlycoNet Investigator develops new chemistry to facilitate drug development and manufacturing
The collaborative project is partnered with CQDM, Simon Fraser University, Amgen, Merck, and Servier.
French 
English